This post shares information about what the OxyMOTION study is and what it involves.
What is the OxyMOTION Study?
For the first time, research has shown that people with AVP deficiency can experience a ‘clinically relevant’ deficiency in oxytocin. In this context, ‘clinically relevant’ means significant enough to cause symptoms that warrant treatment.
This study aims to look at whether oxytocin treatment can improve emotional recognition and stress response for these people. It will look at the effects of oxytocin on someone’s ability to recognise emotions and response to stressful situations.
What is oxytocin?
Oxytocin is a hormone produced in the brain that has positive impacts on social bonding and feelings of love, trust and relaxation. It is made in the brain in response to vasopressin. Therefore, people with AVP deficiency (who do not produce vasopressin) may experience deficiencies in oxytocin, even if they are treated with desmopressin. You can read more about the link between oxytocin and vasopressin here.
Many people with AVP deficiency report symptoms of anxiety, low mood, social withdrawal and reduced quality of life, which may result from oxytocin deficiency.
What does this study involve?
This study will last around 9 weeks. Participants will be screened for initial suitability for the study. If suitable, they will be treated with replacement oxytocin and take part in various study visits where their emotional recognition and stress response will be tested.
How to take part?
If you have any questions or would like to take part in this study, you can contact:
Dr. Svenja Leibnitz: [email protected], phone: 061 328 44 96
Elin Broman: [email protected], phone: 061 328 45 86
